论文部分内容阅读
目的 评价第三代 β 受体阻滞剂卡维地洛防治大鼠急性心肌梗死 (AMI)左室重塑(LVRM)的作用。方法 10 0只雌性SD大鼠AMI术后 2 4h随机分成 :(1)AMI对照组 (n =2 5 ) ;(2 )卡维地洛组 (n =2 5 ) (1mg·kg-1·d-1) ;(3)西拉普利组 (n =2 5 ) (1mg·kg-1·d-1)和 (4)氯沙坦组 (n =2 5 )(3mg·kg-1·d-1) ;另设假手术组 (n =17)。治疗组直接灌胃给药。 4周后行血流动力学测定 ,心脏标本固定和作病理学分析。去除心肌梗死面积 <35 %或 >5 5 %者 ,最终资料完整大鼠 6 3只 ,在以上各组分别为 13、12、12、13和 13只大鼠。结果 AMI各组间梗死面积差异均无显著性 (45 8%～ 4 6 7% ,P均 >0 0 5 )。与假手术组相比 ,AMI组的左室舒张末压 (LVEDP)、容积 (LVV)、重量 (LVW )、室间隔厚度 (STh)和右室重量 (RVW)均显著增加 (P均 <0 0 0 1) ,左室内压最大上升和下降速率 (±dp/dt)及其校正值 (±dp/dt/LVSP)均显著降低 (P均 <0 0 0 1)。与AMI组相比 ,卡维地洛、西拉普利和氯沙坦组的LVEDP和LVV均显著降低 (P <0 0 1～ 0 0 0 1) ,室间隔厚度均显著减小 (P <0 0 0 1) ;LVW和RVW均显著减轻 (P <0 0 5～ 0 0 1) ,±dp/dt及±dp/dt/LVSP均显著升高 (P <0 0 5～ 0 0 0 1)。除左室舒张末压在氯沙坦较卡维地洛组
Objective To evaluate the effect of the third generation β-blocker carvedilol on left ventricular remodeling (LVRM) in rats with acute myocardial infarction (AMI). Methods 10 female SD rats were randomly divided into 2 groups: AMI control group (n = 25), carvedilol group (n = 25) (1 mg · kg-1 · (3 mg · kg-1); (3) cilazapril group (n = 25) (1 mg · kg-1 · d-1) · D-1); another sham operation group (n = 17). The treatment group was administered intragastrically. Four weeks later, hemodynamics, heart specimens were fixed and pathological analysis was performed. Remove myocardial infarction area <35% or> 55%, the final data of 6 3 rats, in each of the above groups were 13,12,12,13 and 13 rats. Results There was no significant difference in infarct size between AMI groups (45.8% ~ 46.7%, P> 0.05). LVEDP, LVV, LVW, STh and RVW in AMI group were significantly higher than those in sham operation group (all P <0) 0 ± 1). The maximal increase and decrease of left ventricular pressure (± dp / dt) and its corrected value (± dp / dt / LVSP) were all significantly decreased (all P <0 0 0 1). LVEDP and LVV in carvedilol, cilazapril, and losartan groups were significantly lower than those in AMI group (P <0.01-0.01), and interventricular septum thickness was significantly reduced (P <0 (P <0.05-0.01), ± dp / dt and ± dp / dt / LVSP both significantly increased (P <0.05-0.001) . In addition to left ventricular end-diastolic pressure in the losartan group than carvedilol